FAQs
Frequently asked questions about diagnosing, treating, and managing MAC lung disease
Questions about diagnosing MAC lung disease
Questions about MAC lung disease progression
Questions about managing MAC lung disease
*MAC is the most common NTM.
AFB=acid-fast bacilli; CT=computed tomography; HRCT=high-resolution computed tomography; NTM=nontuberculous mycobacteria.
References: 1. Park HY, Jeong BH, Chon HR, et al. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest. 2016;150(6):1222-1232. doi:10.1016/j.chest.2016.06.005 2. Liu VX, Winthrop KL, Lu Y, Sharifi H, Nasiri HU, Ruoss SJ. Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection. Ann Am Thorac Soc. 2018;15(10):1169-1176. doi:10.1513/AnnalsATS.201804-245OC 3. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16. doi:10.1513/AnnalsATS.201304-085OC 4. Young JD, Balagopal A, Reddy NS, Schlesinger LS. Differentiating colonization from infection can be difficult. Nontuberculous mycobacterial infections: diagnosis and treatment. J Respir Dis. 2007;28(1):7-18. 5. Aksamit TR, O'Donnell AE, Barker A, et al; Bronchiectasis Research Registry Consortium. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151(5):982-992. doi:10.1016/j.chest.2016.10.055 6. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416. doi:10.1164/rccm.200604-571ST 7. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36. doi:10.1093/cid/ciaa241 8. Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015;36(1):35-41. doi:10.1016/j.ccm.2014.10.003 9. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49(3):1600537. doi:10.1183/13993003.00537-2016 10. Hagiwara E, Katano T, Isomoto K, et al. Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease. Respir Investig. 2019;57(1):54-59. doi:10.1016/j.resinv.2018.08.006 11. van Ingen J, Obradovic M, Hassan M, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex—disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021;15(11):1387-1401. doi:10.1080/17476348.2021.1987891 12. Lin C-Y, Huang H-Y, Hsieh M-H, et al. Impacts of nontuberculous mycobacteria isolates in non-cystic fibrosis bronchiectasis: a 16-year cohort study in Taiwan. Front Microbiol. 2022;13:868435. doi:10.3389/fmicb.2022.868435 13. Lee G, Lee KS, Moon JW, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease: natural course on serial computed tomographic scans. Ann Am Thorac Soc. 2013;10(4):299-306. doi:10.1513/AnnalsATS.201303-062OC 14. Pan SW, Shu CC, Feng JY, et al. Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression. Clin Infect Dis. 2017;65(6):927-934. doi:10.1093/cid/cix479 15. National Jewish Health. Advanced Diagnostic Laboratories. Smear and culture (only) of acid fast bacilli. Accessed May 11, 2026. https://www.nationaljewish.org/for-professionals/diagnostic-testing/advanced-diagnostic-laboratories/smear-culture-acid-fast-bacilli 16. Wang P, Marras TK, Alemao E, Hassan M, Chatterjee A. The incremental burden of nontuberculous mycobacterial lung disease (NTMLD) among patients with bronchiectasis (BE): hospitalizations and ER visits among US Medicare beneficiaries. Presented at: 4th World Bronchiectasis & NTM Conference; December 16-19, 2020; virtual edition. 17. Pathak K, Hart S, Lande L. Nontuberculous mycobacteria lung disease (NTM-LD): current recommendations on diagnosis, treatment, and patient management. Int J Gen Med. 2022;15:7619-7629. doi:10.2147/IJGM.S272690 18. Herrero-Cortina B, Spinou A, Oliveira A, et al. Airway clearance techniques and exercise in people with bronchiectasis: two different coins. Eur Respir J. 2023;62(4):2300741. doi:10.1183/13993003.00741-2023